Exelixis (NASDAQ:EXEL) will announce its earnings results after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $0.12 per share for the quarter.
Shares of Exelixis (NASDAQ:EXEL) opened at $29.18 on Monday. The firm has a market cap of $8,630.00, a PE ratio of 59.55, a price-to-earnings-growth ratio of 0.82 and a beta of 1.84. Exelixis has a 1 year low of $18.03 and a 1 year high of $32.50.
In other news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the sale, the director now owns 64,829 shares in the company, valued at approximately $1,964,318.70. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.10% of the stock is owned by insiders.
Several equities research analysts have weighed in on EXEL shares. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a research report on Tuesday, January 2nd. SunTrust Banks restated a “buy” rating and issued a $38.00 price objective on shares of Exelixis in a research report on Thursday, December 21st. Oppenheimer restated a “hold” rating on shares of Exelixis in a research report on Tuesday, December 19th. Finally, Cann restated a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Exelixis presently has an average rating of “Buy” and a consensus price target of $32.13.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.